Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial.

NCT02726269 is registered in ClinicalTrials.gov with Asofarma de México S.A de C.V. as lead sponsor.

NCT NCT02726269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02726269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial.
Lead sponsor
Asofarma de México S.A de C.V.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
May 31, 2014
Enrollment
230 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori gastritis